(0.27%) 5 475.09 points
(0.13%) 39 170 points
(0.83%) 17 879 points
(0.12%) $83.48
(-0.04%) $2.48
(0.14%) $2 342.20
(0.50%) $29.76
(0.45%) $993.10
(0.04%) $0.931
(0.15%) $10.66
(0.02%) $0.791
(0.01%) $86.76
Live Chart Being Loaded With Signals
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform...
Stats | |
---|---|
Today's Volume | 230 871 |
Average Volume | 802 196 |
Market Cap | 180.94M |
EPS | $-0.730 ( Q1 | 2024-05-14 ) |
Next earnings date | ( $-0.590 ) 2024-08-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.03 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0260 (0.44%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Ra Capital Management, L.p. | Buy | 20 275 | Stock Option (Right to Buy) |
2024-06-20 | Tomsicek Michael John | Buy | 20 275 | Stock Option (Right to Buy) |
2024-06-20 | Shacham Sharon | Buy | 20 275 | Stock Option (Right to Buy) |
2024-06-20 | Dirocco Derek | Buy | 20 275 | Stock Option (Right to Buy) |
2024-06-20 | Baum Charles M | Buy | 20 275 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
30.97 |
Last 74 transactions |
Buy: 13 136 701 | Sell: 16 713 897 |
Volume Correlation
Acrivon Therapeutics, Correlation
10 Most Negative Correlations | |
---|---|
OZEM | -1 |
ATPC | -0.828 |
PFLEX | -0.827 |
BOCNW | -0.826 |
CVKD | -0.826 |
AGNCL | -0.818 |
HDL | -0.818 |
SIYYX | -0.816 |
LESL | -0.813 |
OMIC | -0.813 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Acrivon Therapeutics, Correlation - Currency/Commodity
Acrivon Therapeutics, Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-536 000 (0.00 %) |
EPS: | $-2.74 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-536 000 (0.00 %) |
EPS: | $-2.74 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-1.10M (0.00 %) |
EPS: | $-1.350 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.260 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Acrivon Therapeutics,
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company\'s Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators